NR 508 Week 7 Semaglutide Medication Teaching Plan Example

Medication Teaching Plan: Once-Weekly Semaglutide for a 58-Year-Old Forklift Operator Who Also Takes Glipizide, Built Around the First Four Weeks, the Benefit He Will Never Feel and the One Pain He Must Report

Student Name

College of Nursing, Chamberlain University

NR 508: Advanced Pharmacology

Instructor Name

Month Day, Year

Medication Teaching Plan: Once-Weekly Semaglutide for a 58-Year-Old Forklift Operator Who Also Takes Glipizide, Built Around the First Four Weeks, the Benefit He Will Never Feel and the One Pain He Must Report

Who the Learner Already Is

Mr. O., 58, drives a forklift on day shifts at a distribution warehouse. His type 2 diabetes dates back nine years, and he takes glipizide 10 mg each morning along with metformin, 1,000 mg morning and evening. His hemoglobin A1c is 8.6%. His prescriber is starting semaglutide by subcutaneous injection, 0.25 mg once weekly. He reads well, prefers short videos on his phone to printed handouts, and says he is "not a needle person." His wife manages the household calendar. He has no history of thyroid cancer or pancreatitis, and his eyes were checked last year with mild background retinopathy.

Three facts about him shape the plan. His job involves operating heavy machinery, so hypoglycemia is a safety risk at work. He takes glipizide, which will interact with the new drug. And he has mild retinopathy, which the prescribing information singles out for monitoring.

Objectives You Could Check

By the end of the teaching session, Mr. O. will:

1. Demonstrate an injection with the pen, including checking the solution, dialing the dose, choosing a site and holding the pen in place, without prompting.

2. State the day of the week he will inject and what to do if he misses it.

3. Describe what he is likely to feel in the first weeks and which of those feelings are expected.

4. Name how a low glucose feels to him and the steps he takes before driving the forklift.

5. State the one symptom that means stopping the drug and calling the same day.

Each objective is observable, so the nurse can check it in the room rather than assume it.

The First Four Weeks, on Purpose

The period when a new injectable diabetes drug is most likely to be abandoned is the first month, and the plan spends most of its content there. The label starts semaglutide at 0.25 mg once weekly for four weeks and then increases it to 0.5 mg, with further increases only after at least four weeks at each dose (Novo Nordisk, 2026). Mr. O. should hear that the first dose is a starting dose, chosen to let his stomach adjust, and that his sugars may not change much at first. That prevents the conclusion, in week two, that the drug does not work.

Gastrointestinal effects are the most common reason people stop. In placebo-controlled trials, nausea occurred in 15.8% of patients on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo, with vomiting and diarrhea also more common (Novo Nordisk, 2026). The nurse should tell him plainly: some queasiness in the days after an injection is expected, is more likely after each dose increase, and usually eases. Eating smaller meals, stopping when full and avoiding large fatty meals help. Vomiting or diarrhea that prevents him from keeping fluids down is different: the label warns that dehydration from these effects has led to acute kidney injury, so persistent vomiting is a reason to call.

The Medicine Nobody Feels

The benefits Mr. O. is taking semaglutide for, lower blood glucose and, for people with type 2 diabetes and cardiovascular disease or chronic kidney disease, a lower risk of certain cardiovascular and kidney outcomes, produce no sensation. He will feel the nausea and not the benefit. The plan says so directly and gives him something to watch instead: his home glucose readings over the first two months and his A1c at three months. Many people also lose some weight, which he may notice, but the nurse should not promise it.

There is one effect he may not feel but must still hear about. The prescribing information reports that, in a two-year trial in people with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% of patients on semaglutide and 1.8% on placebo, and advises monitoring patients with a history of retinopathy (Novo Nordisk, 2026). Mr. O. has mild retinopathy, so the plan includes booking his next eye examination before he leaves, rather than leaving it to his annual reminder.

The Interaction That Matters on the Forklift

The label warns that using semaglutide with an insulin secretagogue, such as a sulfonylurea, or with insulin may increase the risk of hypoglycemia, including severe hypoglycemia, and that the dose of the other drug may need to be reduced (Novo Nordisk, 2026). Glipizide is a sulfonylurea. For Mr. O., that means his prescriber may lower the glipizide dose, and he needs to know the signs of low blood sugar, shakiness, sweating, a fast heartbeat, sudden hunger and confusion, and to check his glucose before starting a forklift shift in the first weeks. If it is below 70 mg/dL, he should take fast-acting sugar, such as four glucose tablets or half a cup of juice, wait 15 minutes, and recheck before he climbs onto the forklift.

One Line to Report

People remember one instruction better than seven, so the plan gives him one that must not be missed: severe stomach pain that does not go away, with or without vomiting, sometimes spreading to the back, means stop the injection and call the clinic that day, or go to the emergency department. That is the description of possible pancreatitis in the prescribing information, which directs that the drug be stopped if pancreatitis is suspected (Novo Nordisk, 2026). Other things to report, such as a lump in the neck, changes in vision or a planned procedure under anesthesia, go on a short written list for his wife's calendar, but the single spoken line is the pain.

Method and the Check at the End

Because he prefers video and dislikes needles, the nurse will use the manufacturer's injection video on his phone, then have him handle a demonstration pen, then perform his first real injection in clinic. His wife will be present, since she keeps the calendar; they will choose an injection day together and set a weekly reminder. The missed-dose rule, inject within 5 days of the missed dose, will be written on the reminder itself (Novo Nordisk, 2026).

The check is teach-back, not a question such as "any questions?" The nurse will ask him to show the injection, to say what he will feel in week one, to say what he will do before driving if he feels shaky, and to state the one reason to stop and call. If he cannot do any of these, that part is taught again before he leaves. A phone call at one week, after his second dose, closes the plan and catches problems while they are still small.

References

Novo Nordisk. (2026). Ozempic (semaglutide) injection [Prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79